Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. - Wikidata - wikimedia - TriplyDB

Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.

Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.

http://www.wikidata.org/entity/Q44778139

about

Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Salaam, Tanzania Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.Biochemical and haematological changes in HIV subjects receiving winniecure antiretroviral drug in Nigeria Hepatic profile analyses of tipranavir in Phase II and III clinical trials Seroprevalence of HBV and HIV co-infection in children and outcomes following highly active antiretroviral therapy (HAART) in Uyo, South-South Nigeria Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: possible implications for hepatotoxicity Polypharmacy in the HIV-infected older adult population.Viral hepatitis in HIV infection.CYP3A-mediated generation of aldehyde and hydrazine in atazanavir metabolism.Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors.HIV protease inhibitors and obesity Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients.The effect of highly active antiretroviral therapy on liver function in human immunodeficiency virus-infected pediatric patients with or without hepatitis virus co-infection Effect of anemia on hepatotoxicity of HAART in HIV patients in Benin city The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction.Drug-drug interactions and tolerance in combining antituberculosis and antiretroviral therapy.Treatment of hepatitis C in HIV-coinfected patients.Drug-Induced Liver Injury: Pattern Recognition and Future Directions.Combination lopinavir and ritonavir alter exogenous and endogenous bile acid disposition in sandwich-cultured rat hepatocytes.Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the United States, 2000-2010.Predictors of the change in bilirubin levels over twelve weeks of treatment with atazanavir Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.Idiosyncratic drug-induced liver injury: an overview.Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?Hepatotoxicity and associated risk factors in HIV-infected patients receiving antiretroviral therapy at Felege Hiwot Referral Hospital, Bahirdar, Ethiopia HIV-related liver disease: ARV drugs, coinfection, and other risk factors.Epidemiology of HIV and response to antiretroviral therapy in the middle aged and elderly.Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.Combination therapy of Western drugs and herbal medicines: recent advances in understanding interactions involving metabolism and efflux.Hyperbilirubinaemia in HIV-HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?Prevalence and Clinical Spectrum of Liver Disease in Nepalese HIV-Sero-Positive Patients Undergoing Antiretroviral Therapy: A Cross-Sectional Hospital Based Study.Antitubercular therapy induced liver function tests abnormalities in human immunodeficiency virus infected individuals.Interleukin-2 receptor antagonist immunosuppression and consecutive viral management in living-donor liver transplantation for human immunodeficiency virus/hepatitis C-co-infected patients: a report of 2 cases.Recurrence of another hepatitis B virus escape mutant comes back in a patient infected with HIV and low CD4+ count.Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients.HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes.

P2860

Q27485160-6509CAF2-A9C6-40DC-9A99-06AF629AA869 Q30843946-168C3996-0729-4F33-BA81-E866DCCC8A9F Q33410774-2CD878E8-3662-4231-A02A-D5B4DDACECDB Q33518011-4AB81C82-A1FF-43D7-8084-EB906D872529 Q33751609-8BB1829D-B5DC-4D27-9968-531397D16D51 Q33799279-E7E058C0-9D10-45BC-A2A3-ADDDDAE13CD6 Q34037407-088A7A38-B3D3-44D3-8B58-52B68DA74460 Q34086980-E34F817B-DF8E-4B37-96FE-8C109A70757F Q34702576-CA6C4E67-7D67-4761-9670-F30F18130F6E Q34704820-9A8D312D-8E42-45B4-82C2-C73E6C368682 Q34792983-4BFD04E2-2523-44C4-B301-040356923242 Q35079510-EC9EFE0B-4ED7-4F5B-8F59-02FADA985CB9 Q35079868-8006E48F-B3F5-429E-923C-00328F27AE92 Q35454587-8CEA03DB-2FAF-4943-94B7-801E7402EE25 Q35542957-1A36B32A-0784-419A-8F65-C8FC28DD9942 Q36035557-104F80B4-0BE7-44BC-9498-98C23CB71DA1 Q36235489-6703CD02-11BC-477C-B1E8-3AA31B602B70 Q36409500-E08605BC-B5A9-45BA-8B4B-1A5C68B5B1D8 Q36412863-2FFD7E89-7469-444F-A203-4F4376AC7BF6 Q36497674-1836ACA5-7391-46B9-9038-A2C311A1B3C5 Q36844074-68313F07-A832-4CE6-BE55-0CB94E64D1F8 Q36858737-DCC676DE-BA83-4386-8033-7B8454D2FB08 Q36903921-25EB365D-6302-4379-832F-CA3B73A0D418 Q36972804-ED593B1A-8ABF-4CB5-9152-EC1830CF639C Q36984240-A93B18F6-89FD-415E-8E80-14A47B50E250 Q37173199-8BE574A5-72AE-4C00-88DB-8F5D1240ED3F Q37357476-FFAE06DA-5A8C-460B-A1E7-4EBB01D3C255 Q37391122-3E2A08DC-2DBC-4AA0-9AB8-B5D70D4E9BAF Q37419826-49D423BE-93EB-4048-A568-EE4C8B9BFF22 Q37866289-0DD061A3-8B43-4BCC-9C0A-C935EC9DD675 Q38011807-9D213EAE-F84E-4E61-9651-74E7F624859D Q38804666-7C92A26C-EF17-473B-98DE-A06258980E85 Q40140544-AAB7E1B7-9F88-43D0-ABF9-31E1A2CE0787 Q40358004-686E49DF-2C49-4492-8E48-3B28C0EFFC87 Q40873539-B7585970-18DE-473F-9D55-EBD104A90A63 Q42248669-8CF5A2D8-221D-40A4-A6E7-FF99320EE4E0 Q42990611-703D1B64-9314-4C54-9FEA-8132168F9809 Q44922052-8FEAF5FA-8CEF-45E5-87F6-AE9023DC364A

P2860

Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.

http://www.wikidata.org/entity/Q44778139

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Drug-induced liver injury asso ...... des HIV-1 protease inhibitors.

@en

Drug-induced liver injury asso ...... des HIV-1 protease inhibitors.

@nl

type

label

Drug-induced liver injury asso ...... des HIV-1 protease inhibitors.

@en

Drug-induced liver injury asso ...... des HIV-1 protease inhibitors.

@nl

prefLabel

Drug-induced liver injury asso ...... des HIV-1 protease inhibitors.

@en

Drug-induced liver injury asso ...... des HIV-1 protease inhibitors.

@nl

P1433

Q44778139-4B55B94A-F47F-4444-A1B6-25C9A2F9A0E1

P1476

Q44778139-CAC76841-C852-4937-8C12-345968C51A88

P2093

Q44778139-CA89EE6E-B7EE-4D61-BFFB-76F17D068BD9

P2860

Q44778139-0076E55C-A5F7-44D6-ADD4-42B8F6CA1A1B

Q44778139-073B3531-D4EB-401D-9108-1663E50D2CC8

Q44778139-125C906D-49F4-4641-BCEE-DCB7E7A9ECC9

Q44778139-1E2E4F39-261C-4ED3-A131-6707A8ECE9D0

Q44778139-38E19E22-8169-49BE-B7EA-148E179160EE

Q44778139-4203BD30-22D7-44D9-AB21-C9EE184593C4

Q44778139-4FEDED8B-AB4B-409A-9D64-8F03F0240223

Q44778139-5DC8C13B-C8F9-4B07-BB86-566081B7AA49

Q44778139-6B0FF217-4A66-48B1-8699-D60A3C7BF329

Q44778139-6CD52EBE-DE86-431F-BB55-AF6C9E3596D1

P304

Q44778139-7A6C11B5-616A-4FFD-BF15-25A64B963473

P31

Q44778139-7AE78FB2-0B8E-47C8-9ACE-3B6AAD65C913

P356

Q44778139-8F096551-8FEE-4880-8D7B-6C155CCE2425

P407

Q44778139-BB3DE7A4-FCDF-45FB-90EA-597D70839898

P478

Q44778139-E77AC440-1E33-4419-83E2-3E0BC5C336F6

P577

Q44778139-CFD5C8D2-5E05-4CB0-A721-B0CC965D2340

P5875

Q44778139-A9CFC580-383C-41FC-A7A9-7F219EF98B8D

P698

Q44778139-2354A66B-D688-451B-A520-CE79EE652921

P356

P1433

Clinical Infectious Diseases

P1476

Drug-induced liver injury asso ...... des HIV-1 protease inhibitors.

@en

P2093

Mark S Sulkowski

http://www.w3.org/2001/XMLSchema#string

P2860

Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy.

Mechanism of indinavir-induced hyperbilirubinemia.

Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function.

Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group

Antiretroviral drug toxicity -- a challenge for the hepatologist?

Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus.

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.

Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection.

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.

P304

S90-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/381444

http://www.w3.org/2001/XMLSchema#string

P407

P478

38 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2004-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7573037

http://www.w3.org/2001/XMLSchema#string

P698

14986280

http://www.w3.org/2001/XMLSchema#string